Topic Phase III trials

News Phase III trials

• UCB and Amgen Initiate Sclerostin Antibody Phase 3 program in patients with postmenopausal osteoporosis

  UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president of Resear more

• Medivir announces new studies in phase III program for TMC435

  Medivir AB announced that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.HPC3 more

• Intercell starts a pivotal Phase II/III efficacy study with its Pseudomonas aeruginosa vaccine candidate

  Intercell AG announced the start of a pivotal Phase II/III efficacy trial of its investigational Pseudomonas aeruginosa vaccine. The trial follows an exploratory Phase II study in which lower all-cause mortality rates were observed in the vaccine groups as compared to the control group. The Phase II more

Publications Phase III trials

• First‐line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real‐life’ settings: from clinical trials to clinical practice

  Summary.  Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent nucleos(t)ide analogues (NUCs) recommended as first‐line monotherapies for chronic hepatitis B. In Phase III trials, ETV and TDF demonstrated superior efficacy, and comparable safety compared with other NUCs. In long‐term more

• Imaging Sites of Infection Using a 99mTc-Labeled Folate Conjugate Targeted to Folate Receptor Positive Macrophages

  EC20, a folate-targeted 99mTc based radioimaging agent with a high folate receptor (FR) binding affinity, has been used for both the diagnosis and the staging of FR positive malignancies (currently in phase III trials) and also for the localization of inflamed lesions characterized by the accumulati more

• Cetuximab in non-small-cell lung cancer

  Cetuximab is a chimeric human–mouse anti-EGF receptor monoclonal antibody. In Phase I studies, no dose-limiting toxicities were observed with cetuximab as a single agent or combined with chemotherapy; pharmacokinetic and pharmacodynamic analyses supported 250 mg/m2 weekly administration. Skin toxici more

Market studies Phase III trials

• D-Pharm Ltd. - Strategic SWOT Analysis Review

  D-Pharm LTD.(D-Pharm) is a specialty bio-pharmaceutical company. It is engaged in the design and development of innovative drugs for the treatment of the brain disorders. It has developed two unique platform technologies that generate lipid–like medicines which utilizes lipid specific mechanisms and more

• Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure

  GBI Research, leading business intelligence provider, has released its latest research report, ‘Top R&D Drug Failures - Toxicity and Serious Adverse Events in Late Stage Drug Development are the Major Causes of Drug Failure’, which provides insights into major drug failures during 2005–2010. The 20 more

• Singapore Pharmaceuticals and Healthcare Report Q2 2011

  Singapore has a low risk pharmaceutical market. Despite having an economy that is highly dependent on exports (demand for which is inherently volatile), the country is committed to the continuous provision of quality healthcare, which contributes to a productive and harmonious society. However, retu more

Websites Phase III trials